BioMaxima S.A. Logo

BioMaxima S.A.

Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.

BMX | WAR

Overview

Corporate Details

ISIN(s):
PLBIOMX00015
LEI:
2594007GAALFMXP4YB89
Country:
Poland
Address:
Lublin Vetterów 5, 20-277 Lublin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioMaxima S.A. is a manufacturer in the biotechnology sector specializing in the in vitro diagnostics (IVD) market. The company develops and produces a comprehensive range of solutions for laboratory diagnostics, supporting medical professionals and diagnosticians. Its portfolio encompasses microbiological media, reagents, specialized equipment, and IVD tests. Key application areas include clinical chemistry, haematology, and the diagnosis of infectious diseases, featuring systems for determining drug sensitivity and reference strains for microorganisms.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-27 12:45
Regulatory News Service
Informacja o otrzymaniu dofinansowania w kwocie 1.097.835,17 zł na rozbudowę of…
Polish 1.7 KB
2025-08-08 20:29
Director's Dealing
Zawiadomienie 19 MAR
Polish 8.0 KB
2025-08-08 20:29
Report Publication Announcement
Zawiadomienie od osoby zobowiązanej - Content (PL)
Polish 213 bytes
2025-07-15 12:07
Business and Financial Review
Podpisanie znaczącej umowy - Content (PL)
Polish 581 bytes
2025-06-27 14:00
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 776 bytes
2025-06-25 13:05
Major Shareholding Notification
zal01_Wykaz_akcjonariuszy.pdf
Polish 127.8 KB
2025-06-25 13:05
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów podczas WZ w dniu 25.6.…
Polish 242 bytes
2025-06-25 13:03
Post-Annual General Meeting Information
Uchwały wraz z informacjami.
Polish 244.6 KB
2025-06-25 13:03
Post-Annual General Meeting Information
Uchwały podjęte podcza Walnego Zgromadzenia w dniu 25.6.2025 - Content (PL)
Polish 440 bytes
2025-06-05 12:18
Director's Dealing
zal01_powiadomienie_o_nabyciu_akcji_5_06_2025.pdf
Polish 6.0 KB
2025-06-05 12:18
Board/Management Information
Zawiadomienie od osoby zobowiązanej - Content (PL)
Polish 239 bytes
2025-05-30 17:01
Quarterly Report
Skonsolidowane sprawozdanie finansowe wraz z jednostkową informacją finansową
Polish 1.2 MB
2025-05-29 20:55
Remuneration Information
Sprawodanie o wynagrodzeniach
Polish 2.0 MB
2025-05-29 20:55
Business and Financial Review
Sprawozdanie Rady Nadzorczej
Polish 3.0 MB
2025-05-29 20:55
Pre-Annual General Meeting Information
Zawiadomienie o zwołaniu WZ wraz z projektami uchwał
Polish 315.6 KB

Automate Your Workflow. Get a real-time feed of all BioMaxima S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for BioMaxima S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.